With the advent of more treatments for advanced prostate cancer, determining the best course of treatment for each patient can be challenging. This session will help clinicians to help patients identify next steps in treatment for advanced prostate cancer.

Continuing Education Instructions and Disclosure Information

Contact hours available until 3/23/21.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Planning Committee Disclosures:
Kathy Marchese, ANP, NP, CWOCN

Speakers Bureau - Hollister (non-branded lecture on Intermittent Catheterizaiton)

There are no other disclosures to declare.

Speakers Conflict of Interest Disclosure:
Daniel Shevrin, MD

Speakers Bureau: Bayer (Xofigo) and Sanofi (Docetaxel, Cabazitaxel)

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this continuing nursing education activity, the learner will be able to understand the current landscape of treatment options for advanced prostate cancer and how genomic information can inform the treatment decisions.